McNeil OTC Recalls Slice $900M From J&J's 2010 Sales
This article was originally published in The Tan Sheet
Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.
You may also be interested in...
Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.
The global OTC industry fell back in line with the world gross domestic product in 2010, after significantly outpacing it in 2009. The industry grew 4% in 2010, 1.2 percentage points behind the previous year and 0.2 percentage points below the broader GDP, according to Nicholas Hall, CEO of Nicholas Hall & Company.
Johnson & Johnson's OTC drug recalls are driving interest in homeopathic remedies and other alternative health products, experts and stakeholders say.